AlzeCure Pharma
22.9.2021 14:20:11 CEST | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / September 22, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company is participating at the Naventus Life Science Summit at Grand Hotel in Stockholm on September 29 at 09:25 CEST, where CEO Martin Jönsson will present the company's latest developments.
The event is organized by Naventus Corporate Finance together with Setterwalls, Deloitte, FNCA, Nordnet and Nasdaq.
The presentation will be held in English and live streamed via https://events.naventus.com/ . The presentation will also be available after on AlzeCure's website https://www.alzecurepharma.se/en/presentations-and-interviews/ .
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se , is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se .
Attachments
AlzeCure presents at Naventus Life Science Summit on September 29
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/665112/AlzeCure-Presents-at-Naventus-Life-Science-Summit-on-September-29
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X Reports Increased Engagement as Canadian Facilities Reassess Compliance Exposure Ahead of Carbon Deadlines6.5.2026 15:15:00 CEST | Press release
170% year-over-year increase in traded volumes across TIER and BC OBPS within Karbon-X's trading activity reflects accelerated procurement activity as regulated entities enter the execution phase of the 2026 compliance cycle. CALGARY, AB / ACCESS Newswire / May 6, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today reported increased engagement from regulated facilities across Canada as organizations reassess their compliance position ahead of upcoming reporting and credit surrender deadlines. This includes a 170% increase in traded volumes across TIER and BC OBPS markets within Karbon-X's trading activity compared to the prior year, reflecting increased participation as facilities move into active procurement and execution phases ahead of submission timelines. As the current compliance cycle progresses across Alberta's Technology Innovation and Emissions Red
Global Sports Brand U.S. Polo Assn. Delivers Record $2.7 Billion in Retail Sales for 2025, Targets $4 Billion and 1,500 U.S. Polo Assn. Stores6.5.2026 13:00:00 CEST | Press release
WEST PALM BEACH, FL / ACCESS Newswire / May 6, 2026 / USPA Global, the company that manages U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), today announced that the global sports brand has delivered a record $2.7 billion in worldwide retail sales in 2025, reflecting strong momentum across global markets, channels, and product categories. U.S. Polo Assn. is advancing toward a long‑term goal of $4 billion in global retail sales and 1,500 branded stores worldwide. Record Growth and Global Momentum U.S. Polo Assn.'s 2025 record-breaking performance was driven by continued expansion across both established and emerging markets. North America, the brand's largest region, delivered steady gains, while strong momentum continued across India, the Middle East, Western Europe, and Latin America. Emerging regions, including Asia Pacific and Eastern Europe, also contributed to meaningful growth for the global multi-billion-dollar brand. India remains the bra
Case IQ Advances Its Leadership Position in AI For Investigations with Playbooks6.5.2026 10:00:00 CEST | Press release
Playbooks is a new way to guide AI toward investigative outcomes that ethics, compliance, and HR teams across the EU can trust. LONDON, GB / ACCESS Newswire / May 6, 2026 / Case IQ, the leading provider of end-to-end compliance and risk management solutions for ethics, compliance and HR teams, today announced Playbooks, a new enhancement to Clairia, its AI assistant purpose-built for investigators. Case IQ continues to raise the bar for AI in investigations with Playbooks, which brings greater consistency, control, and confidence to AI-assisted case management. Playbooks enable organizations to shape how AI supports investigators based on their own standards, policies, and operational needs. Organizations feel pressure to adopt AI for investigations, making it difficult to govern, especially while navigating different regulations and standards across EU regions/countries. It's no surprise, as AI adoption is rising: according to our recent investigative benchmark report, which surveyed
Transoft Solutions Acquires CADaptor Solutions6.5.2026 08:00:00 CEST | Press release
Transoft Solutions Expands Temporary Traffic Management Portfolio With Latest Acquisition VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Transoft Solutions, a global leader in transportation engineering, analysis, and operations software, is pleased to announce that it has acquired CADaptor Solutions Ltd, developers of temporary traffic management software. CADaptor Solutions is based out of Huddersfield, UK and was established over 30 years ago. Their CONE Software solution is used widely in the United Kingdom within the Traffic Management industry to aid in the preparation of temporary traffic control diagrams, route diversion and event management schemes. CONE covers all aspects of temporary traffic management design from simple pedestrian footways through to complex multi-lane highway closures and contra-flows. It is used by wide variety of traffic planning related professionals including Highways Agencies, Utility Companies, Local Government, Traffic Management Companies, Civil E
Lawline Exits Beta and Launches Full AI Legal Platform for Businesses and Individuals5.5.2026 15:00:00 CEST | Press release
Sweden's most visited legal platform, recognised among the Nordics' top 9 AI legal startups alongside Legora and others, moves out of beta after surpassing 7,000 registered users, expanding its offering for companies, organisations, and individuals. STOCKHOLM, SE / ACCESS Newswire / May 5, 2026 / Lawline, Sweden's most visited legal platform, today announced the official launch of its AI-driven legal platform, marking its transition out of beta. The launch introduces a significantly expanded product offering aimed at businesses, organisations, and individuals seeking accessible, reliable legal support in everyday decision-making. Lawline AI was first released in beta in February 2026 and has since attracted more than 7,000 registered users. With today's full launch, Lawline introduces a broader suite of capabilities designed to bring legal support closer to where decisions are actually made. "Legal support has traditionally been something you access after the fact, often when problems
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom